<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000390321"><TermName>vatalanib</TermName><TermPronunciation>(va-TAH-la-nib)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors. Also called PTK787/ZK 222584.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713072" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vatalanib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713071" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vatalanib&quot;" language="es" id="_4"/><SpanishTermName>vatalanib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del cáncer. Es un tipo de inhibidor de la proteína tirosina cinasa y de inhibidor de la cinasa receptora del VEGF (factor de crecimiento endotelial vascular). También se llama PTK787/ZK 222584.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-10-25</DateFirstPublished><DateLastModified>2004-10-21</DateLastModified></GlossaryTerm>
